

Vikram M Narayan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8967435/publications.pdf>

Version: 2024-02-01

67
papers

2,115
citations

623734

14
h-index

254184

43
g-index

69
all docs

69
docs citations

69
times ranked

5560
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	13.7	1,395
2	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. <i>Lancet Oncology</i> , The, 2021, 22, 107-117.	10.7	172
3	A systematic assessment of Cochrane reviews and systematic reviews published in high-impact medical journals related to cancer. <i>BMJ Open</i> , 2018, 8, e020869.	1.9	47
4	The fragility of statistically significant findings from randomised controlled trials in the urological literature. <i>BJU International</i> , 2018, 122, 160-166.	2.5	34
5	Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice. <i>International Journal of Urology</i> , 2017, 24, 352-360.	1.0	32
6	The impact of squamous histology on survival in patients with muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 353.e17-353.e24.	1.6	32
7	Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design. <i>Journal of Urology</i> , 2021, 205, 1612-1621.	0.4	31
8	The landscape of systematic reviews in urology (1998 to 2015): an assessment of methodological quality. <i>BJU International</i> , 2017, 119, 638-649.	2.5	30
9	Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma. <i>Cancer</i> , 2021, 127, 1974-1983.	4.1	26
10	The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer. <i>Journal of Urology</i> , 2018, 199, 74-80.	0.4	23
11	Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. <i>The Cochrane Library</i> , 2019, 2019, CD012832.	2.8	22
12	Improved Reporting of Randomized Controlled Trials in the Urologic Literature. <i>European Urology</i> , 2016, 70, 1044-1049.	1.9	17
13	Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. <i>The Cochrane Library</i> , 2022, 2022, CD012867.	2.8	17
14	Clinical and Genomic Considerations for Variant Histology in Bladder Cancer. <i>Current Oncology Reports</i> , 2019, 21, 23.	4.0	16
15	A critical appraisal of biomarkers in prostate cancer. <i>World Journal of Urology</i> , 2020, 38, 547-554.	2.2	16
16	Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. <i>The Cochrane Library</i> , 0, , .	2.8	14
17	Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane Review. <i>BJU International</i> , 2022, 130, 730-740.	2.5	13
18	Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. <i>The Cochrane Library</i> , 0, , .	2.8	12

#	ARTICLE	IF	CITATIONS
19	Racial disparities and considerations for active surveillance of prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 214-220.	1.4	11
20	Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. <i>A Cochrane Rapid Review. The Cochrane Library</i> , 2018, 7, CD012838.	2.8	11
21	Blue versus white light for transurethral resection of non-muscle invasive bladder cancer. <i>The Cochrane Library</i> , 2021, 2021, CD013776.	2.8	11
22	Early Stage Cancer in Older Adults. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 238-241.	2.0	9
23	Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. <i>European Urology</i> , 2022, 81, 223-228.	1.9	8
24	Early Stage Cancer in Older Adults: Prostate Avoiding Overtreatment and Undertreatment. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 238-241.	2.0	6
25	Bladder changes after catheterizable channel creation in adults with cerebral palsy who are in chronic urinary retention. <i>Neurourology and Urodynamics</i> , 2019, 38, 165-170.	1.5	6
26	The role of the urologist, BCG vaccine administration, and SARS-CoV-2: An overview. <i>BJUI Compass</i> , 2020, 1, 87-92.	1.3	6
27	Intravesical gemcitabine for non-muscle invasive bladder cancer. <i>The Cochrane Library</i> , 2021, 2021, CD009294.	2.8	6
28	Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review. <i>Investigative and Clinical Urology</i> , 2021, 62, 623.	2.0	6
29	Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2073-2084.	4.1	6
30	The future of clinical trials in urological oncology. <i>Nature Reviews Urology</i> , 2019, 16, 722-733.	3.8	5
31	Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology. <i>American Journal of Clinical Pathology</i> , 2021, 156, 895-905.	0.7	5
32	Hypoxic upregulation of preproendothelin-1 gene expression is associated with protein tyrosine kinase-PI3K signaling in cultured lung vascular endothelial cells. <i>International Journal of Clinical and Experimental Medicine</i> , 2009, 2, 87-94.	1.3	5
33	A cellular model to mimic exhaled cigarette smoke-induced lung microvascular endothelial cell injury and death. <i>International Journal of Clinical and Experimental Medicine</i> , 2010, 3, 223-32.	1.3	5
34	Defining the publication source of high-quality evidence in urology: an analysis of EvidenceUpdates. <i>BJU International</i> , 2016, 117, 861-866.	2.5	4
35	Evaluating Region of Interest Measurement Strategies to Characterize Upper Urinary Tract Stones on Computerized Tomography. <i>Journal of Urology</i> , 2017, 197, 715-722.	0.4	4
36	Genomic Analysis and Treatment Response of a Bladder Urothelial Carcinoma With Sarcomatoid Variant Histology. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e888-e892.	1.9	4

#	ARTICLE	IF	CITATIONS
37	TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 811-821.	3.4	4
38	Longitudinal impact of bladder cancer diagnosis on common psychiatric disorders. <i>Cancer Medicine</i> , 2021, 10, 8412-8420.	2.8	4
39	Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 340-340.	1.6	4
40	Expression of Nectin-4 and PD-L1 in bladder cancer with variant histology.. <i>Journal of Clinical Oncology</i> , 2022, 40, 529-529.	1.6	4
41	Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. <i>The Cochrane Library</i> , 2022, 2022, CD012867.	2.8	4
42	Re: Efficacy and Safety of Prostatic Arterial Embolization: Systematic Review with Meta-Analysis and Meta-Regression. <i>Journal of Urology</i> , 2017, 198, 215-216.	0.4	3
43	The Effects of Population-based Prostate-specific Antigen Screening Beginning at Age 40. <i>Urology</i> , 2017, 110, 127-133.	1.0	3
44	Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 247-254.	1.6	3
45	Lentiviral interferon: A novel method for gene therapy in bladder cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 141-157.	4.4	3
46	Re: Richard J. Sylvester, Steven E. Canfield, Thomas B.L. Lam, et al. Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. <i>Eur Urol</i> 2017;71:811-819. <i>European Urology</i> , 2017, 72, e91-e92.	1.9	2
47	Testosterone supplementation in men with sexual dysfunction. <i>The Cochrane Library</i> , 0, , .	2.8	2
48	Bacillus Calmette-Guérin Salvage Therapy. <i>Urologic Clinics of North America</i> , 2020, 47, 1-4.	1.8	2
49	Extramammary Paget's Disease of genitourinary origin. <i>Current Opinion in Urology</i> , 2021, Publish Ahead of Print, .	1.8	2
50	Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. <i>A Cochrane Rapid Review</i> . <i>The Cochrane Library</i> , 2017, , .	2.8	1
51	Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2019, 75, 1034-1035.	1.9	1
52	The History of Urology at the Minneapolis Veterans Affairs Health Care System. <i>Urology</i> , 2019, 123, 7-11.	1.0	1
53	Immunotherapy for advanced or metastatic urothelial carcinoma. <i>The Cochrane Library</i> , 0, , .	2.8	1
54	Blue versus white light for transurethral resection of non-muscle invasive bladder cancer. <i>The Cochrane Library</i> , 2020, , .	2.8	1

#	ARTICLE	IF	CITATIONS
55	Oncologic Equipose Between Robotic and Open Radical Cystectomy. Journal of Endourology, 2021, 35, 1168-1176.	2.1	1
56	Reducing Postoperative Opioids for Outpatient Endoscopic Urological Surgery: A Resident Driven Quality Improvement Initiative. Urology Practice, 2020, 7, 378-383.	0.5	1
57	The Role of Surgery in Initially Metastatic Urothelial Carcinoma: Informing a Definitive Trial. European Urology Oncology, 2020, 3, 102-103.	5.4	0
58	Perioperative systemic chemo-immunotherapy for upper urinary tract urothelial carcinoma. The Cochrane Library, 2020, , .	2.8	0
59	Editorial Comment. Journal of Urology, 2021, 205, 1351-1351.	0.4	0
60	Reply by Authors. Journal of Urology, 2021, 205, 1620-1621.	0.4	0
61	A Helpful Tool in the Renal Surgery Armamentarium: Dorsal Lumbotomy nephrectomy for Tumor in Patients with End-Stage Renal Disease. Urology, 2021, 153, 327-332.	1.0	0
62	Altering the microbiome for immunotherapyâ€resistant urological tumorsâ€”An intriguing but still early concept. Cancer, 2021, , .	4.1	0
63	Focal Therapy for Prostate Cancer: A Molecular Biology Approach with TRAIL. Current Clinical Urology, 2017, , 347-354.	0.0	0
64	EDITORIAL COMMENT. Urology, 2021, 156, 197-198.	1.0	0
65	Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review. Bladder Cancer, 2022, , 1-17.	0.4	0
66	Clinical outcomes in advanced urothelial cancer (UC) patients who experienced immune-related adverse events (irAEs) after immune checkpoint inhibitor monotherapy (ICI).. Journal of Clinical Oncology, 2022, 40, 544-544.	1.6	0
67	Assessing the Presence of Spin in Abstracts of Systematic Reviews and Meta-Analyses on Testicular Cancer Treatment, Screening, and Quality of Life: Cross-Sectional Analysis. The Journal of Scientific Practice and Integrity, 0, , .	0.5	0